Lupin's Tarapur facility receives EIR from US FDA
Deepthi | Myequity news | Date : 27-11-2018 13:00:00 IST
Lupin received the Establishment Inspection Report (EIR) on the completion of an inspection by the US FDA (United States Food & Drug Administration) at its facility in Tarapur, Maharashtra. The inspection conducted between August 27 and August 31, 2018 concluded with one inspectional observation. About Lupin Limited
Founded in 1992, the Tarapur facility is a state-of-the-art unit for manufacturing Active Pharmaceuticals Ingredients (API), both fermentation-based and synthetic.
Commenting on the development, Nilesh Gupta, Managing Director, Lupin said, "For Lupin, meeting and exceeding global quality and procedural standards has always been paramount. We are committed to upholding the highest levels of quality and compliance standards across all our facilities ."
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded &generic formulations, biotechnology products and APls globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.